Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 8, 2014

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2032

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Temozolomide

Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).

RADIATION

Subventricular Zone radiation

"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"

RADIATION

Neural Progenitor Cell Sparing radiation

"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"

Trial Locations (3)

21287

RECRUITING

The SKCCC at Johns Hopkins, Baltimore

Unknown

RECRUITING

Sibley Memorial Hospital, Washington D.C.

RECRUITING

Suburban Hospital, Bethesda

All Listed Sponsors
collaborator

Reading Health System Foundation

UNKNOWN

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER